newsfilter
← Latest News
Business Wire·

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m.